Table 1 QLQ-CIPN20, PRO-CTCAE™, and TNSc© Sample statistics at each study visit
Measure | Mean (SD) | Median (range) | Proportion at floor (%) | Proportion at ceiling (%) |
|---|---|---|---|---|
PRO-CTCAE numbness and tingling severity | ||||
T1 (n = 140) | 0.79 (0.78) | 1 (0–3) | 57 (40.7%) | 0 |
T2 (n = 137) | 0.91 (0.84) | 1 (0–3) | 50 (36.5%) | 0 |
T3 (n = 138) | 1.08 (0.88) | 1 (0–4) | 40 (29%) | 1 (0.07%) |
T4 (n = 123) | 1.03 (0.83) | 1 (0–3) | 35 (28.5%) | 0 |
PRO-CTCAE numbness and tingling interference | ||||
T1 (n = 139) | 0.25 (0.54) | 0 (0–2) | 111 (79.9%) | 0 |
T2 (n = 140) | 0.49 (0.79) | 0 (0–3) | 93 (66.4%) | 0 |
T3 (n = 138) | 0.55 (0.76) | 0 (0–3) | 83 (60.1%) | 0 |
T4 (n = 126) | 0.52 (0.72) | 0 (0–3) | 76 (60.3%) | 0 |
QLQ-CIPN20 sensory | ||||
T1 (n = 140) | 7.84 (10.51) | 3.70 (0–55.56 | 56 (40%) | 0 |
T2 (n = 140) | 11.02 (11.02) | 7.41 (0–55.56) | 33 (23.6%) | 0 |
T3 (n = 138) | 11.92 (11.88) | 7.41 (0–55.56) | 33 (23.9%) | 0 |
QLQ-CIPN20 motor | ||||
T1 (n = 140) | 5.15 (7.60) | 0 (0–37.5) | 75 (53.6%) | 0 |
T2 (n = 139) | 7.61 (9.74) | 4.17 (0–50) | 58 (41.7%) | 0 |
T3 (n = 138) | 8.49 (10.57) | 4.17 (0–54.17) | 54 (39.1%) | 0 |
0–10 NRS of worst CIPN pain Intensity | ||||
T1 (n = 138) | 1.41 (1.98) | 0 (0–9) | 71 (51.4%) | 0 |
T2 (n = 139) | 1.99 (2.41) | 1 (0–10) | 61 (43.9%) | 0 |
T3 (n = 138) | 1.97 (2.16) | 1 (0–9) | 58 (42%) | 0 |
TNSc© | ||||
T3 (n = 118) | 6.75 (2.9) | 7 (1–13) | 0 | 0 |